Efficacy and safety of alogliptin in a pediatric patient with maturity-onset diabetes of the young type 1

The first-line pharmacological treatment for patients with maturity-onset diabetes of the young type 1 (MODY1) and maturity-onset diabetes of the young type 3 (MODY3) are sulfonylureas (SUs) or insulin. However, several reports have suggested the possibility of using incretin-associated drugs, inclu...

Descripción completa

Detalles Bibliográficos
Autores principales: Tonouchi, Ryosuke, Mine, Yusuke, Aoki, Masako, Okuno, Misako, Suzuki, Junichi, Urakami, Tatsuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society for Pediatric Endocrinology 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537215/
https://www.ncbi.nlm.nih.gov/pubmed/28804210
http://dx.doi.org/10.1297/cpe.26.183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537215/
https://www.ncbi.nlm.nih.gov/pubmed/28804210
http://dx.doi.org/10.1297/cpe.26.183

Ejemplares similares